EMA officials on how to distinguish ‘merely new’ from ‘truly better’ drugs

A trio of top EMA officials have suggested that a mutual understanding among decision-makers on clinical trial design could increase transparency of competing drugs’ comparative efficacy and help regulators, payers and other stakeholders determine whether new drugs actually have an added benefit over existing

Read the full 449 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE